Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Blood biomarkers for Alzheimer’s disease in clinical practice and trials

Hansson, Oskar LU orcid ; Blennow, Kaj LU ; Zetterberg, Henrik LU and Dage, Jeffrey (2023) In Nature Aging 3(5). p.506-519
Abstract

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic work-up of Alzheimer’s disease (AD) in clinical practice. This is very timely, considering the recent development of anti-amyloid-β (Aβ) immunotherapies. Several assays for measuring phosphorylated tau (p-tau) in plasma exhibit high diagnostic accuracy in distinguishing AD from all other neurodegenerative diseases in patients with cognitive impairment. Prognostic models based on plasma p-tau levels can also predict future development of AD dementia in patients with mild cognitive complaints. The use of such high-performing plasma p-tau assays in the clinical practice of specialist memory clinics would reduce the need for more costly investigations... (More)

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic work-up of Alzheimer’s disease (AD) in clinical practice. This is very timely, considering the recent development of anti-amyloid-β (Aβ) immunotherapies. Several assays for measuring phosphorylated tau (p-tau) in plasma exhibit high diagnostic accuracy in distinguishing AD from all other neurodegenerative diseases in patients with cognitive impairment. Prognostic models based on plasma p-tau levels can also predict future development of AD dementia in patients with mild cognitive complaints. The use of such high-performing plasma p-tau assays in the clinical practice of specialist memory clinics would reduce the need for more costly investigations involving cerebrospinal fluid samples or positron emission tomography. Indeed, blood-based biomarkers already facilitate identification of individuals with pre-symptomatic AD in the context of clinical trials. Longitudinal measurements of such biomarkers will also improve the detection of relevant disease-modifying effects of new drugs or lifestyle interventions.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Nature Aging
volume
3
issue
5
pages
14 pages
publisher
Springer
external identifiers
  • pmid:37202517
  • scopus:85160094360
DOI
10.1038/s43587-023-00403-3
language
English
LU publication?
yes
id
16a5844f-6ea2-46a3-9bb0-c11dc3898640
date added to LUP
2023-08-22 14:02:14
date last changed
2024-04-20 02:18:11
@article{16a5844f-6ea2-46a3-9bb0-c11dc3898640,
  abstract     = {{<p>Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic work-up of Alzheimer’s disease (AD) in clinical practice. This is very timely, considering the recent development of anti-amyloid-β (Aβ) immunotherapies. Several assays for measuring phosphorylated tau (p-tau) in plasma exhibit high diagnostic accuracy in distinguishing AD from all other neurodegenerative diseases in patients with cognitive impairment. Prognostic models based on plasma p-tau levels can also predict future development of AD dementia in patients with mild cognitive complaints. The use of such high-performing plasma p-tau assays in the clinical practice of specialist memory clinics would reduce the need for more costly investigations involving cerebrospinal fluid samples or positron emission tomography. Indeed, blood-based biomarkers already facilitate identification of individuals with pre-symptomatic AD in the context of clinical trials. Longitudinal measurements of such biomarkers will also improve the detection of relevant disease-modifying effects of new drugs or lifestyle interventions.</p>}},
  author       = {{Hansson, Oskar and Blennow, Kaj and Zetterberg, Henrik and Dage, Jeffrey}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{506--519}},
  publisher    = {{Springer}},
  series       = {{Nature Aging}},
  title        = {{Blood biomarkers for Alzheimer’s disease in clinical practice and trials}},
  url          = {{http://dx.doi.org/10.1038/s43587-023-00403-3}},
  doi          = {{10.1038/s43587-023-00403-3}},
  volume       = {{3}},
  year         = {{2023}},
}